Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nandini Dey

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Cancer Research|April 6, 2019
Decision making in precision oncology: an issue of mutational contextualityNandini Dey, Pradip De
International Journal of Molecular Sciences|November 17, 2019
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An OpportunityPradip De, Nandini Dey
Cancers|July 9, 2022
Precision Medicine in Solid Tumors: How Far We Traveled So Far?Nandini Dey, Pradip De
Cancers|October 23, 2021
Cancer-Associated Fibroblast Functions as a Road-Block in Cancer TherapyPradip De, Jennifer Aske, Nandini Dey
Cancers|February 3, 2021
Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCRNandini Dey, Jennifer Aske, Pradip De
American Journal of Cancer Research|January 9, 2020
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted futureBrett Rozeboom, Nandini Dey, Pradip De
Methods in Molecular Biology (Clifton, N.J.)|May 25, 2021
A Triple-Parameter-Based Laboratory-Friendly Fluorescence Imaging to Identify Apoptosis in Live CellsPradip De, Jennifer Carlson Aske, Nandini Dey
Cells|April 28, 2019
RAC1 Takes the Lead in Solid TumorsPradip De, Jennifer Carlson Aske, Nandini Dey
Pharmacology & Therapeutics|February 21, 2017
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsNandini Dey, Pradip De, Brian Leyland-Jones
American Journal of Translational Research|December 23, 2015
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsNandini Dey, Pradip De, Leyland-Jones Brian
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Cancer Research|April 6, 2019
Decision making in precision oncology: an issue of mutational contextualityNandini Dey, Pradip De
International Journal of Molecular Sciences|November 17, 2019
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An OpportunityPradip De, Nandini Dey
Cancers|July 9, 2022
Precision Medicine in Solid Tumors: How Far We Traveled So Far?Nandini Dey, Pradip De
Cancers|October 23, 2021
Cancer-Associated Fibroblast Functions as a Road-Block in Cancer TherapyPradip De, Jennifer Aske, Nandini Dey
Cancers|February 3, 2021
Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCRNandini Dey, Jennifer Aske, Pradip De
American Journal of Cancer Research|January 9, 2020
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted futureBrett Rozeboom, Nandini Dey, Pradip De
Methods in Molecular Biology (Clifton, N.J.)|May 25, 2021
A Triple-Parameter-Based Laboratory-Friendly Fluorescence Imaging to Identify Apoptosis in Live CellsPradip De, Jennifer Carlson Aske, Nandini Dey
Cells|April 28, 2019
RAC1 Takes the Lead in Solid TumorsPradip De, Jennifer Carlson Aske, Nandini Dey
Pharmacology & Therapeutics|February 21, 2017
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsNandini Dey, Pradip De, Brian Leyland-Jones
American Journal of Translational Research|December 23, 2015
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsNandini Dey, Pradip De, Leyland-Jones Brian
Pageof 6